US Interventional Cardiology Devices Market

The report "US Interventional Cardiology Devices Market by Type (Stents, Balloons, Structural Heart, Angio Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration, Guidewire, Introducer Sheaths), End User (Hospitals, Cardiac Centers) - Forecast to 2031" is projected to be valued at USD 12.82 billion in 2026 and USD 17.75 billion by 2031, growing at a CAGR of 6.7% during the forecast period .

Browse 380 market data Tables and 75 Figures spread through 400 Pages and in-depth TOC on "US Interventional Cardiology Devices Market, By Type (Stents, Balloons, Structural Heart, Angio Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration, Guidewire, Introducer Sheaths), End User (Hospitals, Cardiac Centers) - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/us-interventional-cardiology-devices-market-224885471.html

The expansion of the US interventional cardiology devices market is mainly attributed to the high incidence of cardiovascular diseases, including coronary artery disease, peripheral artery disease, and structural heart conditions. The rise in the aging population, which often requires catheter-based interventions, contributes to the market growth. The continuous stream of innovations in the field—drug-eluting stents, drug-coated balloons, and various intravascular imaging (IVUS and OCT) and physiologic assessment tools—is increasing the accuracy of procedures and the clinical efficacy. The wide insurance coverage for percutaneous coronary interventions and structural heart procedures is a significant reason behind the quick market growth. Furthermore, the development of high-tech cath lab infrastructure and highly skilled physicians also contributes to the market growth. The upward shift in preference for transradial access, the increased number of procedures being performed in hospitals and outpatient surgical centers, and the continuous investment in innovation and clinical research by top manufacturers drive the market.

Drug-eluting stents segment is expected to grow at the highest CAGR from 2026 to 2031

The drug-eluting stents segment is expected to record the highest CAGR in the US interventional cardiology devices market due to the persistent issue of coronary artery disease and the strong clinical preference for PCI over surgical revascularization for suitable patients. The widespread preference for drug-eluting stents can be attributed to their proven ability to reduce restenosis and repeat revascularization compared with bare-metal stents. This also supports their continued use as the standard of care in most coronary interventions. Technological advancements, such as thinner strut designs, better polymer coatings, bioresorbable polymers, and enhanced drug formulations, improve safety profiles and long-term clinical outcomes to the point that they can even encourage the use of these stents in complex and high-risk lesions. Along with favorable reimbursement for PCI procedures, the extensive clinical evidence supporting DES efficacy and the high physician familiarity further reinforce the demand. Besides, the rise in PCI volumes, the increase in treatment of the elderly and comorbid patients, and the strong product innovation and clinical trial activity of the leading manufacturers drive the segment.

Ambulatory surgery centers segment accounted for the second-largest market share in 2025

The growth of the ambulatory surgery centers segment in the US interventional cardiology devices market is mainly due to the increased number of cardiac surgeries being performed in outpatient care facilities instead of the more costly inpatient hospital setting, as one of the major benefits of interventional cardiology devices, which include smaller-profile catheters, transradial access technologies, and improved hemostasis systems. These technological advances have made the procedures safer, allowing same-day discharge in selected internees, such as PCI and diagnostic angiography. Moreover, the healthcare system being pressured to reduce overall treatment costs and favorable reimbursement policies for outpatient cardiovascular procedures lead to ASC adoption. Patients prefer less time in the hospital, quicker recovery, and lower risk of infections. Other drivers include increased physician ownership and participation in ASCs, along with the growing acceptance of outpatient cardiac interventions by payers.

Key Market Players

Some prominent players operating in the US  interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), and BIOTRONIK SE & Co. KG (Germany).

Don’t miss out on business opportunities in Keyword. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/